Covered recipient · General Payments record
PAVEL KLEIN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$82,048.25
124 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $31,800.00 | 10 |
| Consulting Fee | $21,094.14 | 2 |
| Travel and Lodging | $21,045.07 | 43 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,255.00 | 2 |
| Food and Beverage | $2,854.04 | 67 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SK Life Science, Inc. | $41,211.70 | 49 |
| Dr.Reddy's Laboratories,Inc. | $24,366.68 | 13 |
| Neurelis, Inc. | $7,562.68 | 16 |
| Jazz Pharmaceuticals Inc. | $4,275.59 | 5 |
| UCB, Inc. | $2,159.51 | 13 |
| Eisai Inc. | $1,931.34 | 1 |
| Sumitomo Pharma America, Inc. | $142.92 | 12 |
| Axsome Therapeutics, Inc. | $138.76 | 3 |
| LivaNova USA, Inc. | $57.60 | 3 |
| UPSHER-SMITH LABORATORIES LLC | $44.70 | 2 |
| Lilly USA, LLC | $41.52 | 2 |
| Marinus Pharmaceuticals, Inc. | $29.99 | 1 |
| ABBVIE INC. | $26.35 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $24.03 | 1 |
| ARGENX US, INC. | $18.44 | 1 |
| Celgene Corporation | $16.44 | 1 |
Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PAVEL KLEIN
NPI 1770528648 · CMS profile ID 216326
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
BETHESDA, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1770528648?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PAVEL KLEIN, NPI 1770528648, CMS profile ID 216326. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770528648?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). PAVEL KLEIN, NPI 1770528648, CMS profile ID 216326. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770528648?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- PAVEL KLEIN, NPI 1770528648, CMS profile ID 216326, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1770528648?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
124 matching records · $82,048.25 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–124 of 124.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| LivaNova USA, Inc. | $20.35 | 02/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1043015337 | CMS |
| Sumitomo Pharma America, Inc. | $14.42 | 02/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1030879415 | CMS |
| UCB, Inc. | $36.00 | 02/15/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021387145 | CMS |
| UCB, Inc. | $46.00 | 02/15/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021387153 | CMS |
| UCB, Inc. | $48.00 | 02/15/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021387163 | CMS |
| UCB, Inc. | $76.34 | 02/15/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021387171 | CMS |
| UCB, Inc. | $322.90 | 02/15/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021387177 | CMS |
| UCB, Inc. | $374.20 | 02/15/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021387185 | CMS |
| Sumitomo Pharma America, Inc. | $8.63 | 02/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1030879427 | CMS |
| UCB, Inc. | $20.89 | 02/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021400533 | CMS |
| Lilly USA, LLC | $21.31 | 02/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032013017 | CMS |
| Neurelis, Inc. | $16.51 | 02/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050921493 | CMS |
| UCB, Inc. | $16.95 | 01/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021400515 | CMS |
| UPSHER-SMITH LABORATORIES LLC | $17.54 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 994133645 | CMS |
| Axsome Therapeutics, Inc. | $20.83 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056200799 | CMS |
| SK Life Science, Inc. | $54.68 | 01/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054735849 | CMS |
| SK Life Science, Inc. | $50.01 | 01/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054736573 | CMS |
| SK Life Science, Inc. | $60.00 | 01/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054736583 | CMS |
| SK Life Science, Inc. | $20.96 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054735829 | CMS |
| SK Life Science, Inc. | $65.00 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054735837 | CMS |
| SK Life Science, Inc. | $166.80 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054735843 | CMS |
| Sumitomo Pharma America, Inc. | $16.44 | 01/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1030879399 | CMS |
| Celgene Corporation | $16.44 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015564331 | CMS |
| ABBVIE INC. | $26.35 | 01/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997662527 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $89,657.97 | 23 |
| PY2024 | Recipient | $1,975.00 | 1 |
| PY2024 | Principal investigator | $270,329.90 | 89 |
| PY2023 | Recipient | $420.00 | 1 |
| PY2023 | Principal investigator | $365,143.97 | 97 |
| PY2022 | Recipient | $6,400.00 | 2 |
| PY2022 | Principal investigator | $170,649.28 | 25 |
| PY2021 | Recipient | $17,120.00 | 3 |
| PY2021 | Principal investigator | $724,237.07 | 94 |
| PY2020 | Recipient | $12,880.00 | 13 |
| PY2020 | Principal investigator | $635,503.64 | 63 |
| PY2019 | Recipient | $45,044.91 | 9 |
| PY2019 | Principal investigator | $279,662.75 | 22 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
23 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SK Life Science, Inc. | $9,891.87 | 12/01/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP3089C025 | No dispute reported | 06/30/2026 | 1252274881 |
| Principal investigator 1 | SK Life Science, Inc. | $2,147.89 | 11/12/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274841 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,915.00 | 10/20/2025 | Non-covered Recipient Entity WCG Clinical, Inc. WCG IRB, LLC | A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures | No dispute reported | 06/30/2026 | 1233746314 |
| Principal investigator 1 | ABBVIE INC. | $9,617.70 | 10/14/2025 | Non-covered Recipient Entity PAVEL KLEIN | A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures | No dispute reported | 06/30/2026 | 1202516741 |
| Principal investigator 1 | SK Life Science, Inc. | $226.05 | 10/01/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274851 |
| Principal investigator 1 | SK Life Science, Inc. | $4,227.96 | 08/22/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274831 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,317.60 | 07/09/2025 | Non-covered Recipient Entity MID ATLANTIC EPILEPSY AND SLEEP CENTER LLC | A STUDY OF SOTICLESTAT AS AN ADD-ON THERAPY IN CHILDREN AND ADULTS WITH DRAVET SYNDROME OR LENNOX-GASTAUT SYNDROME | No dispute reported | 06/30/2026 | 1223282490 |
| Principal investigator 1 | SK Life Science, Inc. | $3,673.11 | 05/28/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274793 |
| Principal investigator 1 | SK Life Science, Inc. | $564.68 | 05/28/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274797 |
| Principal investigator 1 | SK Life Science, Inc. | $1,694.69 | 05/28/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274799 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,742.20 | 05/23/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND SLEEP CENTER | A STUDY OF SOTICLESTAT AS AN ADD-ON THERAPY IN CHILDREN AND ADULTS WITH DRAVET SYNDROME OR LENNOX-GASTAUT SYNDROME | No dispute reported | 06/30/2026 | 1223280286 |
| Principal investigator 1 | Immedica Pharma US, Inc. | $2,527.54 | 04/29/2025 | Non-covered Recipient Entity MIDATLANTIC EPILEPSY & SLEEP | A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC) | No dispute reported | 06/30/2026 | 1225392411 |
| Principal investigator 1 | SK Life Science, Inc. | $2,622.60 | 03/25/2025 | Non-covered Recipient Entity Mid-Atlantic Epilepsy & Sleep Center | YKP3089C040 | No dispute reported | 06/30/2026 | 1252274889 |
| Principal investigator 1 | SK Life Science, Inc. | $12,102.03 | 03/25/2025 | Non-covered Recipient Entity Mid-Atlantic Epilepsy & Sleep Center | YKP3089C040 | No dispute reported | 06/30/2026 | 1252274891 |
| Principal investigator 1 | SK Life Science, Inc. | $534.30 | 03/21/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274823 |
| Principal investigator 1 | SK Life Science, Inc. | $1,717.98 | 03/21/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274825 |
| Principal investigator 1 | SK Life Science, Inc. | $5,790.75 | 03/12/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274817 |
| Principal investigator 1 | SK Life Science, Inc. | $2,664.90 | 03/11/2025 | Non-covered Recipient Entity Mid-Atlantic Epilepsy & Sleep Center | YKP3089C040 | No dispute reported | 06/30/2026 | 1252274887 |
| Principal investigator 1 | SK Life Science, Inc. | $5,338.89 | 02/14/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274813 |
| Principal investigator 1 | Immedica Pharma US, Inc. | $3,500.00 | 02/12/2025 | Non-covered Recipient Entity MIDATLANTIC EPILEPSY & SLEEP | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE) | No dispute reported | 06/30/2026 | 1225392323 |
| Principal investigator 1 | Immedica Pharma US, Inc. | $8,500.00 | 02/12/2025 | Non-covered Recipient Entity MIDATLANTIC EPILEPSY & SLEEP | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE) | No dispute reported | 06/30/2026 | 1225392325 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,352.36 | 01/22/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | A STUDY OF SOTICLESTAT AS AN ADD-ON THERAPY IN CHILDREN AND ADULTS WITH DRAVET SYNDROME OR LENNOX-GASTAUT SYNDROME | No dispute reported | 06/30/2026 | 1223274327 |
| Principal investigator 1 | SK Life Science, Inc. | $1,987.87 | 01/03/2025 | Non-covered Recipient Entity MID-ATLANTIC EPILEPSY AND | YKP509C003 | No dispute reported | 06/30/2026 | 1252274821 |